Sarepta Therapeutics, Inc.
Clinical trials sponsored by Sarepta Therapeutics, Inc., explained in plain language.
-
New gene therapy trial hopes to restore muscle protein in duchenne boys
Disease control Recruiting nowThis study tests a one-time gene therapy called delandistrogene moxeparvovec in 83 people with Duchenne muscular dystrophy. The goal is to see if it is safe and helps the body make dystrophin, a protein missing in Duchenne. The trial is now enrolling non-ambulatory participants (…
Phase: PHASE1 • Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug SRP-1005 takes first step against Huntington's
Disease control Recruiting nowThis study tests a new drug called SRP-1005 in 32 adults with Huntington's disease. It is the first time this drug is being tested in humans, so the main goal is to check safety and how the body processes the drug. Participants will receive either SRP-1005 or a placebo by injecti…
Phase: PHASE1 • Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC